Back to Search
J MUHLESTEIN, MD
MD
Cardiovascular Disease Physician
NPI: 1689683435IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
1878711205(UT)
Education
UNIVERSITY OF UTAH SCHOOL OF MEDICINE
Class of 1984
Research & Publications (20)
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
PMID 16843192·J Am Coll Cardiol·2006
2-rct
Improved long-term survival associated with stent deployment during percutaneous coronary interventions: results from a registry of 3399 patients.
PMID 16084167·Am Heart J·2005
8-other
Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction.
PMID 15260513·Drugs Aging·2004
6-review
Early effects of statins in patients with coronary artery disease and high C-reactive protein.
PMID 15518602·Am J Cardiol·2004
4-observational
Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention.
PMID 12891207·Am Heart J·2003
4-observational
Secondary prevention of coronary artery disease with antimicrobials: current status and future directions.
PMID 14727986·Am J Cardiovasc Drugs·2002
6-review
Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality.
PMID 11165956·Am J Cardiol·2001
8-other
Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study.
PMID 11023928·Circulation·2000
3-trial
Chlamydia pneumoniae-induced atherosclerosis in a rabbit model.
PMID 10839748·J Infect Dis·2000
6-review
Antibiotic therapy for treatment of Chlamydia to prevent coronary heart disease events.
PMID 11122763·Curr Atheroscler Rep·2000
7-preclinical
Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease.
PMID 11034939·Circulation·2000
8-other
Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures.
PMID 19473299·J Cardiovasc Electrophysiol·2009
3-trial
Potential of mid-infrared spectroscopy to aid the triage of patients with acute chest pain.
PMID 19475134·Analyst·2009
8-other
Exceptional mortality prediction by risk scores from common laboratory tests.
PMID 19486718·Am J Med·2009
4-observational
Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study.
PMID 19602672·J Cardiovasc Pharmacol Ther·2009
8-other
Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors.
PMID 19659615·Pacing Clin Electrophysiol·2009
4-observational
Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently.
PMID 19422587·Pacing Clin Electrophysiol·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5121 S COTTONWOOD ST # L6
MURRAY, UT 84107 - Phone
- (801) 507-4760
Quick Facts
- NPI
- 1689683435
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 42
- Publications
- 20
Are you this provider?
Claim Your Profile